Praxis says its essential tremor drug failed a Phase 3 readout but plans to complete study
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price $PRAX down roughly 40%. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
